New drug BIVV020 tested for rare blood disorder
NCT ID NCT04269551
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a single dose of the drug BIVV020 in 12 adults with cold agglutinin disease, a rare condition where the immune system mistakenly attacks red blood cells. The main goal was to see if the drug is safe and tolerable. Researchers also looked at how it affects red blood cell breakdown and the immune system's complement pathway.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BIVV020 (a drug given as a single intravenous injection)
What this could lead to
If successful, this could point toward a new treatment option for cold agglutinin disease, a rare autoimmune condition that destroys red blood cells.
What could go wrong
This is a very early, small Phase 1b trial with only 12 participants. It primarily tests safety, not effectiveness, so the drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HAEMOLYTIC ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :2760001
Essen, 45147, Germany
-
Investigational Site Number :3800001
Milan, Milano, 20122, Italy
-
Investigational Site Number :5280001
Amsterdam, 1105AZ, Netherlands
-
Investigational Site Number :5780001
Bergen, 5021, Norway
-
Investigational Site Number :8260001
London, London, City of, NW1 2PJ, United Kingdom
-
Investigational Site Number :8400002
Fayetteville, Georgia, 30214, United States
-
Investigational Site Number :8400004
Seattle, Washington, 98108, United States
-
Investigational Site Number :8400006
The Bronx, New York, 10467, United States
-
Investigational Site Number :8400008
Pittsburgh, Pennsylvania, 15232, United States
-
Investigational Site Number :8400009
St Louis, Missouri, 63110, United States